ERBB2 and breast carcinoma: For example, the incidence of ILD was much higher in patients with HER2-positive breast cancer when treated with TDX-d compared with trastuzumab emtansine (28% vs. 15%), which may be related to the presence of a tumor-selective cleavable linker and a higher drug-to-antibody ratio in TDX-d [25,26].